going gray tirzepatide GLP-1 Drugs from the Market This before and after is

G.WangY

Lancet 392 , 15191529

The trade-off is real, and the regulatory floor sits lower

Ozempic Weight Loss First Month: Clinical Evidence & Expectations First-month weight loss on Ozempic varies significantly based on starting dose, metabolic factors, and individual response patterns

Nonetheless, certain obese individuals at very high risk of T2D, atherosclerotic cardiovascular disease, heart failure, or renal failure could benefit from such a monotherapy

This contraindication reflects the theoretical concern that GLP-1 receptor stimulation could promote recurrence or progression of residual C-cell disease, even though human C-cells express minimal GLP-1 receptors